The Neuroendocrine Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Neuroendocrine Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuroendocrine Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuroendocrine Carcinoma and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Neuroendocrine Carcinoma by 34 companies/universities/institutes. The top development phase for Neuroendocrine Carcinoma is phase ii with 22 drugs in that stage. The Neuroendocrine Carcinoma pipeline has 37 drugs in development by companies and one by universities/ institutes. Some of the companies in the Neuroendocrine Carcinoma pipeline products market are: Bristol-Myers Squibb, F. Hoffmann-La Roche and Suzhou Zelgen Biopharmaceutical.
The key targets in the Neuroendocrine Carcinoma pipeline products market include Programmed Cell Death Protein 1, Delta Like Protein 3, and CD3.
The key mechanisms of action in the Neuroendocrine Carcinoma pipeline product include Programmed Cell Death Protein 1 Antagonist with eight drugs in Phase III. The Neuroendocrine Carcinoma pipeline products include 13 routes of administration with the top ROA being Intravenous and seven key molecule types in the Neuroendocrine Carcinoma pipeline products market including Monoclonal Antibody, and Small Molecule.
Neuroendocrine Carcinoma overview
Neuroendocrine carcinoma (NEC) is a rare type of cancer that arises from neuroendocrine cells, which are cells that have both nerve and hormone functions. NEC can occur in various organs, such as the lungs, pancreas, stomach, intestines, appendix, rectum, breast, kidney, ovaries, or testicles. NEC can be classified into well-differentiated or poorly differentiated tumors, depending on how they look under the microscope and how fast they grow. Well-differentiated NECs are usually slow-growing and have a better prognosis than poorly differentiated NECs, which are aggressive and have a worse prognosis. NECs can also be functional or nonfunctional, depending on whether they produce excess hormones that cause symptoms. Functional NECs can cause carcinoid syndrome, which is a group of symptoms such as flushing, diarrhea, wheezing, and heart problems. Nonfunctional NECs do not cause any hormonal symptoms. The diagnosis and treatment of a NEC depends on the location, type, grade, stage, and hormone status of the tumor.
For a complete picture of Neuroendocrine Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
